JP2009538318A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538318A5
JP2009538318A5 JP2009512164A JP2009512164A JP2009538318A5 JP 2009538318 A5 JP2009538318 A5 JP 2009538318A5 JP 2009512164 A JP2009512164 A JP 2009512164A JP 2009512164 A JP2009512164 A JP 2009512164A JP 2009538318 A5 JP2009538318 A5 JP 2009538318A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
dione
amino
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009512164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/012495 external-priority patent/WO2007139939A2/en
Publication of JP2009538318A publication Critical patent/JP2009538318A/ja
Publication of JP2009538318A5 publication Critical patent/JP2009538318A5/ja
Pending legal-status Critical Current

Links

Images

JP2009512164A 2006-05-26 2007-05-24 併用療法において免疫調節化合物を用いる方法及び組成物 Pending JP2009538318A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80860206P 2006-05-26 2006-05-26
PCT/US2007/012495 WO2007139939A2 (en) 2006-05-26 2007-05-24 Methods and compositions using immunomodulatory compounds in combination therapy

Publications (2)

Publication Number Publication Date
JP2009538318A JP2009538318A (ja) 2009-11-05
JP2009538318A5 true JP2009538318A5 (https=) 2010-07-29

Family

ID=38606531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512164A Pending JP2009538318A (ja) 2006-05-26 2007-05-24 併用療法において免疫調節化合物を用いる方法及び組成物

Country Status (11)

Country Link
EP (1) EP2023912A2 (https=)
JP (1) JP2009538318A (https=)
KR (1) KR20090014393A (https=)
CN (1) CN101495111A (https=)
AU (1) AU2007267928A1 (https=)
CA (1) CA2652888A1 (https=)
IL (1) IL195412A0 (https=)
MX (1) MX2008014912A (https=)
RU (1) RU2426542C2 (https=)
WO (1) WO2007139939A2 (https=)
ZA (1) ZA200809956B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510983A (ja) * 2008-01-29 2011-04-07 セルジーン コーポレイション Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
CA2868302A1 (en) * 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
KR20210021602A (ko) * 2013-08-22 2021-02-26 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
EP3616754A1 (en) 2013-08-22 2020-03-04 Vanda Pharmaceuticals Inc. Cancer treatment
CN112063586A (zh) * 2014-03-26 2020-12-11 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法
WO2015175916A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers
US20240360411A1 (en) * 2021-09-01 2024-10-31 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
EP4612128A4 (en) 2022-11-04 2025-09-10 Bristol Myers Squibb Co COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2752124A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
BR0315609A (pt) * 2002-10-24 2005-08-23 Celgene Corp Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
KR20060109979A (ko) * 2003-12-02 2006-10-23 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation

Similar Documents

Publication Publication Date Title
JP2009538318A5 (https=)
Pusic et al. Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells
KR100711181B1 (ko) 골수형성이상 증후군의 치료 및 관리를 위한 면역조절화합물의 사용 방법 및 이를 포함하는 조성물
KR101483802B1 (ko) 외투층 세포 림프종의 치료에 있어서 3-(4-아미노-1-옥소-1,3-디히드로-이소인돌-2-일)-피페리딘-2,6-디온의 용도
JP4865027B2 (ja) 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
US20050143420A1 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
EP1267848A1 (en) Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
CN103025330A (zh) 使用来那度胺和阿扎胞苷的组合疗法治疗骨髓增生异常综合症的方法
KR20140008282A (ko) 혈액암의 치료
CA2672000A1 (en) Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma
US20080051431A1 (en) Methods and compositions using immunomodulatory compounds in combination therapy
EP1267929A2 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
JP2013231086A (ja) 化学療法の強化方法
US10752612B2 (en) PLK4 inhibitors
WO2017042944A1 (ja) フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
RU2008151713A (ru) Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении
WO2001064217A2 (en) Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
JP2009545620A5 (https=)
WO2010123049A1 (ja) 癌治療のための選択的ｅｐ４受容体拮抗物質
AU2017300738A1 (en) Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
Annageldiyev et al. The PI3K/AKT pathway inhibitor ISC-4 induces apoptosis and inhibits growth of leukemia in preclinical models of acute myeloid leukemia
JP2018516936A5 (https=)
EP1261343A2 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EP1261342A2 (en) Farnesyl protein transferase inhibitor combinations
WO2001064197A2 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives